The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: A network meta-analysis

BMC Psychiatry

Volumn 17, Issue 1, 2017, Pages

  Zhang, Yangyu ^a   Liu, Yingyu ^a   Su, Yingying ^a   You, Yueyue ^a   Ma, Yue ^a   Yang, Guang ^a   Song, Yan ^a   Liu, Xinyu ^a   Wang, Mohan ^a   Zhang, Lili ^a   Kou, Changgui ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Antipsychotic drug; Glucose change; Network meta analysis; RCTs

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; CLOZAPINE; GLUCOSE; HALOPERIDOL; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; INSULIN; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADVERSE OUTCOME; ARTICLE; COMPARATIVE STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG EFFECT; METABOLISM; NETWORK META-ANALYSIS;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; HUMANS; INSULIN; LURASIDONE HYDROCHLORIDE; NETWORK META-ANALYSIS; PIPERAZINES; RISPERIDONE; SCHIZOPHRENIA; THIAZOLES;

EID: 85034670008     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-017-1539-0     Document Type: Article

References (63)

1. Collaborators GBoDS. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800.
2. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's general practice Rsearch database. Arch Gen Psychiatry. 2007;64(2):242-9.
3. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123-31.
4. Reininghaus U, Dutta R, Dazzan P, Doody GA, Fearon P, Lappin J, Heslin M, Onyejiaka A, Donoghue K, Lomas B, et al. Mortality in schizophrenia and other psychoses: a 10-year follow-up of the SOP first-episode cohort. Schizophr Bull. 2015;41(3):664-73.
5. Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ. 2013;346:f2539.
6. Ösby U, Correia N, Brandt L, Ekbom A, Sparén P. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res. 2000;45(1-2):21-8.
7. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, Mcmurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65.
8. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. Clozapine and associated diabetes mellitus. J Clin Psychiatry. 1997;58(3):108.
9. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- v. Second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406.
10. De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8(1):15-22.
11. Argo T, Carnahan R, Barnett M, Holman TL, Perry PJ. Diabetes prevalence estimates in schizophrenia and risk factor assessment. Ann Clin Psych Official J Am Acad Clin Psych. 2011;23(2):117.
12. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233-40.
13. Cowie CC, Rust KF, Byrd Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care. 2006;29(6):1263.
14. Gerstein HC. Is glucose a continuous risk factor for cardiovascular mortality? Diabetes Care. 1999;22(5):659.
15. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61(10):742-9.
16. Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents. Psychopharmacology. 2001;154(2):205-12.
17. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63(10):856-65.
18. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry. 2004;65(Suppl 18):36-46.
19. Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Patsch JR, et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry. 2003;64(12):1436-9.
20. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002;71(3):239-57.
21. Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K, Jara B. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74-85.
22. Polcwiartek C, Vang T, Bruhn CH, Hashemi N, Rosenzweig M, Nielsen J. Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. Psychopharmacology. 2016;233(21-22):3663-72.
23. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1-93.
24. Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res. 2003;59(1):1-6.
25. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry. 2001;58(12):1172-6.
26. Kwong K, Hornbuckle K, Signa W, Cavazzoni P, Hutchins D. Higher incidences of diabetes mellitus during exposure to antipsychotics - findings from a retrospective cohort study in the US. Eur Neuropsychopharmacol. 2001;11(01):S279-80.
27. Gianfrancesco F, Grogg A, Mahmoud R, Nasrallah H. Association of new-onset diabetes and antipsychotics: findings from a large health plan database. Eur Neuropsychopharmacol. 2001;11(01):S259.
28. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 2003;56(2):164-70.
29. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306-18.
30. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733-59.
31. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-33.
32. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-62.
33. Jiao ZY, Liang L, Teng M, Leng KA, Beng SL, Furukawa TA, Baldessarini RJ, Peng LB, Kang S. Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. Bjpsych Open. 2016;2(1):59-66.
34. Statacorp B: Stata statistical software. Release 5. 2010.
35. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163-71.
36. Donegan S, Williamson P, D'Alessandro U, Tudur Smith C. Assessing key assumptions of network meta-analysis: a review of methods. Res Synth Methods. 2013;4(4):291-323.
37. Caldwell DM, Gibb DM, Ades AE. Validity of indirect comparisons in meta-analysis. Cold Spring Harb Perspect Biol. 2007;369(9558):1-10.
38. Song F, Xiong T, Parekh-Bhurke S, Loke YK, Sutton AJ, Eastwood AJ, Holland R, Chen YF, Glenny AM, Deeks JJ, et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ. 2011;343:d4909.
39. Salanti G, Marinho V, Higgins JPT. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol. 2009;62(8):857-64.
40. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions - journal of clinical epidemiology. J Clin Epidemiol. 2008;61(5):455-63.
41. Arneson GA. Phenothiazine derivatives and glucose metabolism. J Neuro-Oncol. 1964;5(3):181-5.
42. Ai D, Roper TA, Riley JA. Diabetic ketoacidosis and clozapine. Postgrad Med J. 1998;74(874):493-4.
43. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment. Diabetes Care. 1999;22(1):176-7.
44. Kamran A, Doraiswamy PM, Jane JL, Hammett EB, Dunn L. Severe hyperglycemia associated with high doses of clozapine. Am J Psychiatry. 1994;151(9):1395.
45. Maule S, Giannella R, Lanzio M, Villari V. Diabetic ketoacidosis with clozapine treatment. Diabetes Nutr Metab. 1999;12(2):187-8.
46. Cohen D. Atypical antipsychotics and new onset diabetes mellitus: an overview of the literature. Pharmacopsychiatry. 2004;37(1):1-11.
47. Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT. Adverse effects and laboratory parameters of high-dose Olanzapine vs. Clozapine in treatment-resistant schizophrenia. Ann Clin Psychiatry. 2011;15(3-4):181-6.
48. Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res. 2009;110(1-3):95-102.
49. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll CU, Kane JM. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63(5):524-9.
50. Melkersson KI. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychosis. J Clin Psychiatry. 1999;60(11):783-91.
51. Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. Ann Pharmacother. 2000;34(7-8):865-7.
52. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, Sachs G, Stern TA. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999;40(5):438-43.
53. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, Tang JS. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology. 2006;186(4):572-8.
54. Association ADAAP. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-72.
55. Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol. 2013;36(6):223-38.
56. Spina E, Zoccali R. Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. Expert Opin Drug Metab Toxicol. 2008;4(5):629-38.
57. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, Mcevoy JP, Cooper TB, Chakos M, Lieberman JA. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160(2):290-6.
58. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169-79.
59. Citrome L, Cucchiaro J, Sarma K, Phillips D, Silva R, Tsuchiya S, Loebel A. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165-76.
60. Correll CU, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. Cns Spectrum. 2016;21(5):393-402.
61. Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A. Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study. Depress Anxiety. 2016;33(5):424-34.
62. Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and Olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957-67.
63. Oh GH, Yu JC, Choi KS, Joo EJ, Jeong SH. Simultaneous comparison of efficacy and tolerability of second-generation antipsychotics in schizophrenia: mixed-treatment comparison analysis based on head-to-head trial data. Psychiatry Investigation. 2015;12(1):46-54.